FDA Orders GLP-1 Label Warnings About a Potential Rare Eye Risk

Reporting by U.S. Food and Drug Administration · November 9, 2026

The FDA is requiring GLP-1 medicine labels to address a potential increased risk of NAION, a rare optic-nerve condition. Its safety communication explains the evidence and symptoms, directing patients with sudden vision changes to seek professional medical attention promptly.

This is HUB News’s original summary. Read the complete report at U.S. Food and Drug Administration.